Inflammatory Bowel Disease Center Leadership
The Inflammatory Bowel Disease Center leadership team is dedicated to providing comprehensive, compassionate care.
Feza Remzi, MD, Center Director
Dr. Remzi has more than 20 years of experience in the surgical management of IBD. He specializes in pelvic pouch surgery and complex abdominopelvic reoperative surgery, using a wide range of minimally invasive techniques. He is also one of the few colorectal surgeons in the world who specializes in helping people who are experiencing problems from prior pelvic pouch surgery. As an international expert in colorectal surgery, he has published many articles and book chapters on the surgical management of IBD, ileal J-pouch surgery, and reoperative abdominopelvic surgery.
David P. Hudesman, MD, Center Co-Director
Dr. Hudesman specializes in the diagnosis, treatment, and care of people who have IBD. He is highly trained in endoscopic procedures, such as colonoscopy, chromoendoscopy, and upper endoscopy. Dr. Hudesman’s research efforts are focused on patient outcomes, disease monitoring, and clinical trials for the treatment of IBD. As co-director, Dr. Hudesman also oversees the services and coordination of medical care at the center, with the goal of partnering with each patient to provide individualized, state-of-the-art, and seamless multidisciplinary care.
Lisa B. Malter, MD, Director, Education
Dr. Malter specializes in the diagnosis of IBD and the treatment and care of people with IBD, including Crohn’s disease and ulcerative colitis. In addition to overseeing the training of doctors in IBD at NYU Langone Health, Dr. Malter leads the center’s educational efforts, which include free health seminars for patients and the public.
Seymour Katz, MD, Director, Outreach Programs
Dr. Katz, who specializes in the diagnosis and treatment of IBD, is based on Long Island at our Nassau County location, where he cares for people with complex Crohn’s disease and ulcerative colitis. He and his team also offer numerous clinical trials, designed to make promising new investigational treatment options available to the patients who need them.